Last updated: March 2, 2026
What is the indicated drug?
NDC 63323-0136 corresponds to Fentanyl Sublingual Tablets, 100 mcg (Fentanyl Sublingual Tablets, USP, 100 mcg). Fentanyl is a potent synthetic opioid primarily prescribed for severe pain management, often in cancer or post-surgical contexts. Its high potency and risk of diversion result in strict regulatory oversight.
Market Overview
Market Size and Demand
The fentanyl sublingual tablet segment caters to specialized pain management within hospitals, clinics, and specialty pharmacies. The global opioid analgesics market was valued at approximately USD 11.9 billion in 2022, with fentanyl representing a significant share due to prescribing volume and potency.
The US accounts for over 70% of the global fentanyl market, driven by high prescription rates and ongoing opioid use within pain management protocols. Recent regulatory concerns and the push toward abuse deterrent formulations have influenced prescribing behaviors.
Regulatory Status and Impact
The drug is classified as a Schedule II controlled substance, reflecting high abuse potential. The Drug Enforcement Administration (DEA) enforces strict quotas and distribution controls. The recent rescheduling of certain fentanyl products, increased oversight, and federal monitoring have constrained supply chains temporarily but also boosted demand for approved formulations.
Key Competitors
- Actiq (fentanyl citrate) lozenge
- Duragesic (fentanyl transdermal system)
- Subsys (fentanyl sublingual spray)
- Abstral (fentanyl sublingual tablets)
Market share distribution favors products with abuse deterrent features. NDC 63323-0136 competes directly with generic formulations and branded products.
Pricing Analysis
Historical Pricing Trends
The retail price per unit for fentanyl sublingual tablets has shown volatility, influenced by regulatory changes, manufacturing costs, and litigation risk.
| Year | Estimated Price per 100 mcg Tablet | Comments |
|--------|--------------------------------------+------------------------------------------|
| 2019 | USD 6.50 | Standard list price |
| 2020 | USD 6.80 | Slight increase |
| 2021 | USD 7.20 | Market expansion, supply chain issues |
| 2022 | USD 7.50 | Regulatory tightening, demand up |
| 2023 | USD 8.00 | Continued price escalation |
Current Pricing Drivers
- Regulatory constraints: limit supply and elevate costs.
- Manufacturing complexity: strict quality control adds costs.
- Market scarcity: limited generic competition for specific formulations.
- Insurance coverage: reimbursement levels influence actual patient out-of-pocket costs.
Pricing Projections (2024-2028)
Assuming market stabilization with regulatory compliance and increased demand, prices are projected to grow modestly.
| Year |
Estimated Price per 100 mcg Tablet |
Assumptions |
| 2024 |
USD 8.20 |
Slight inflation, stable regulatory environment |
| 2025 |
USD 8.60 |
Increase in manufacturing efficiency |
| 2026 |
USD 9.00 |
Market saturation, moderate competition |
| 2027 |
USD 9.40 |
Potential policy shifts, generic entry increases |
| 2028 |
USD 9.80 |
Continued demand, price elasticity testing |
Market Risks and Opportunities
Risks
- Regulatory changes: tighten restrictions or impose additional controls.
- Litigation: potential for lawsuits related to misuse or adverse outcomes.
- Market shifts: rise of abuse deterrent or alternative pain management approaches.
Opportunities
- Expansion into emerging markets where opioid prescribing is less regulated.
- Development of abuse-deterrent formulations to gain regulatory approval and market share.
- Partnering with specialty pharmacies focused on pain management.
Key Takeaways
- The drug faces a saturated but tightly regulated market dominated by branded and generic fentanyl products.
- Price per unit has risen steadily, reflecting manufacturing costs and regulatory impacts.
- Growth through 2028 projected at an annual rate of 4–6%, assuming stable regulatory and market conditions.
- Risks include policy shifts and increased competition from abuse-deterrent or non-opioid therapies.
- Market opportunities exist mainly in emerging economies and through reformulation efforts.
FAQs
1. How does regulatory policy influence fentanyl price projections?
Regulations limit supply, increase compliance costs, and affect prescribing, all of which can drive prices up or cause supply shortages affecting prices.
2. What are the primary competitors for NDC 63323-0136?
They include other fentanyl formulations like Actiq, Duragesic patches, Subsys spray, and Abstral tablets.
3. How significant is the impact of abuse-deterrent features on market prices?
Abuse-deterrent features typically increase manufacturing costs but can command higher prices due to improved safety profiles and regulatory favorability.
4. What factors could accelerate price increases?
Tighter regulations, increased demand due to shortage of alternative therapies, or cost inflation in manufacturing.
5. Are emerging markets a growth opportunity for this drug?
Yes, particularly where opioid prescribing practices are less restrictive, creating potential for market expansion.
References
- MarketWatch. (2023). Opioids Market Analysis. https://www.marketwatch.com/
- US Food & Drug Administration (FDA). (2022). Opioid analgesics classifications and regulations. https://www.fda.gov/
- IQVIA. (2023). Global Prescription Drug Market Report. https://www.iqvia.com/
- DEA. (2023). Controlled Substances Schedule. https://www.dea.gov/
- Bloomberg Industry Analysis. (2023). Opioid Market Trends. https://www.bloomberg.com/
